Daiichi Sankyo Company, Limited
Fiscal Year 2025 Q3 Financial Results Briefing
For the cumulative third quarter of fiscal 2025, revenue was JPY 1,533.5 billion (YoY +12.1%), core operating income was JPY 249.2 billion (YoY +8.8%), and net income attributable to owners of parent was JPY 217.4 billion (YoY +4.2%), reflecting profit growth.
Key Figures
- Revenue: JPY 1,533.5 billion (YoY +12.1%)
- Core Operating Income: JPY 249.2 billion (YoY +8.8%)
- Net Income Attributable to Owners of Parent: JPY 217.4 billion (YoY +4.2%)
AI要約
Overview of Business Performance
For the cumulative third quarter of fiscal 2025, revenue was JPY 1,533.5 billion, a 12.1% increase year-over-year, and core operating income was JPY 249.2 billion, up 8.8% year-over-year. Key products Enhertu® and Datopotamab Deruxtecan® showed steady growth, contributing to the revenue increase. Operating income declined year-over-year due to the impact of one-time income and expenses, but net income increased by 4.2%. The exchange rates were USD/JPY 148.75 and EUR/JPY 171.84.
Segment Revenue Changes and Product Trends
The revenue increase drivers include an 88.5 billion yen increase in Enhertu® and a 22.5 billion yen increase in Datopotamab Deruxtecan® within the Oncology Business Unit, along with revenue growth in Datopotamab Deruxtecan®, Belsomra, Lixiana, and Talicia by the Japan Business Unit and others. Conversely, declines were seen in Inavir and Daiichi Sankyo Espha. The global product Enhertu® maintained the number one new patient share in major countries and steadily expanded its new patient share in first-line treatment of HER2-positive breast cancer in the U.S. Datopotamab Deruxtecan® sales approximately 1.5 times increased from the previous quarter-end, achieving sales growth exceeding expectations in the U.S. and Japan.
